ストックスクリーナーアプリを入手
106.33
0.51%
-0.54
アフターアワーズ：
106.65
0.32
+0.30%
前日終値:
$106.87
開ける：
$106.94
24時間の取引高:
1.76M
Relative Volume:
0.78
時価総額：
$20.87B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
24.17
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
+4.46%
1か月 パフォーマンス:
+11.45%
6か月 パフォーマンス:
+55.02%
1年 パフォーマンス:
+50.74%
1日の値動き範囲:
$104.70
$106.94
1週間の範囲:
$101.02
$112.29
52週間の値動き範囲:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
106.33 | 20.98B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.59 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.00 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
796.00 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.91 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
333.99 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - ulpravda.ru
Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Why Incyte Corporation (ICY) stock is a strong buy callGap Down & Expert Approved Momentum Ideas - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Can Incyte Corporation stock hit analyst price targets2025 Key Lessons & Safe Entry Momentum Stock Tips - ulpravda.ru
Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals - Chartmill
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win - FirstWord
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Spotlight On: Incyte's win in first-line DLBCL points to incremental growth opportunity for Monjuvi - FirstWord
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Canada
Incyte (INCY) Achieves Key Milestones in Phase 3 Lymphoma Study - GuruFocus
Incyte’s tafasitamab meets primary endpoint in frontMIND trial - Investing.com
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi - Business Wire
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trend - Chartmill
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
INCYTE CORPORATION CMNRo Khanna Congressional Trade on May. 02, 2017 - Quiver Quantitative
Incyte takes JPMorgan stage as investors look for pipeline signals - MSN
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals - MyChesCo
Incyte Corporation (INCY) Stock Analysis: Evaluating Growth Potential Amid Strong Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews
Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts - MarketBeat
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options - MyChesCo
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. - MarketBeat
Pacer Advisors Inc. Grows Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
2.33%
大文字化:
|
ボリューム (24 時間):